BIOGEN INC.

BIIB Nasdaq CIK: 0000875045

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 225 BINNEY STREET, CAMBRIDGE, MA, 02142
Mailing Address 225 BINNEY STREET, CAMBRIDGE, MA, 02142
Phone 7814642000
Fiscal Year End 1231
EIN 330112644

Financial Overview

FY2025

$1.63B
Net Income
$28.05B
Total Assets
$11.33B
Total Liabilities

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events February 11, 2026 View on SEC
4 Insider stock transaction report February 10, 2026 View on SEC
4 Insider stock transaction report February 10, 2026 View on SEC
4 Insider stock transaction report February 10, 2026 View on SEC
4 Insider stock transaction report February 10, 2026 View on SEC
4 Insider stock transaction report February 10, 2026 View on SEC
4 Insider stock transaction report February 10, 2026 View on SEC
4 Insider stock transaction report February 10, 2026 View on SEC
4 Insider stock transaction report February 10, 2026 View on SEC
4 Insider stock transaction report February 10, 2026 View on SEC

Annual Reports

10-K February 6, 2026
  • Strategic acquisitions of Reata Pharmaceuticals ($7.3B) and Human Immunology Biosciences (initial $1.8B) are diversifying Biogen's pipeline into rare diseases and immunology.
  • Successful initial revenue generation from new drug launches including SKYCLARYS ($150M), QALSODY ($20M), and ZURZUVAE ($10M) in 2024.
View Analysis

Material Events

8-K Acquisition January 14, 2026
High Impact
  • Strategic decision to invest in future growth by expanding their research pipeline.
  • Active efforts to bring new treatments to market, potentially leading to new treatment options for patients.
View Analysis

Insider Trading

SELL 1 insiders 2 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.